Filing Details
- Accession Number:
- 0001104659-25-003876
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-01-15 21:17:06
- Reporting Period:
- 2025-01-13
- Accepted Time:
- 2025-01-15 21:17:06
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1442836 | Mersana Therapeutics Inc. | MRSN | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1645755 | Alejandra Carvajal | C/O Mersana Therapeutics, Inc. 840 Memorial Drive Cambridge MA 02139 | Svp, Chief Legal Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2025-01-13 | 8,958 | $0.00 | 72,674 | No | 4 | M | Direct | |
Common Stock | Disposition | 2025-01-14 | 3,330 | $0.66 | 69,344 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Restricted Stock Unit | Disposition | 2025-01-13 | 8,958 | $0.00 | 8,958 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
17,917 | No | 4 | M | Direct |
Footnotes
- Represents shares of common stock received upon vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on January 13, 2023.
- Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2023. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the Reporting Person.
- Each RSU represents the contingent right to receive one share of common stock of the Issuer.
- 25% of the total number of RSUs granted vested on January 13, 2025, and the remainder shall vest thereafter in equal annual installments over the next two years.